At low concentrations, KYNA acts as a non-antagonistic inhibitor of the α7 nicotinic acetylcholine receptor (α7nAch-R), and at high concentrations, it acts as an antagonistic inhibitor of NMDAR (Figure 2B), reducing glutamate and acetylcholine transmission, which may lead to cognitive decline. The gene discussed is CHRNA7; the disease is Mental deterioration.